Our tumor MSCs expressed the following surface antigens: CD73, CD90, CD105, and HLA-class I ≥95% and CD34, CD14, CD45, CD31, and HLA-DR ≤ 5% (Figure 1B). This evidence concerns the gene NT5E and neoplasm.